Discovery of the first Mycobacterium tuberculosis MabA (FabG1) inhibitors through a fragment-based screening.
Sign Up to like & getrecommendations! Published in 2020 at "European journal of medicinal chemistry"
DOI: 10.1016/j.ejmech.2020.112440
Abstract: Mycobacterium tuberculosis (M.tb), the etiologic agent of tuberculosis, remains the leading cause of death from a single infectious agent worldwide. The emergence of drug-resistant M.tb strains stresses the need for drugs acting on new targets.… read more here.
Keywords: maba; tuberculosis; discovery first; maba fabg1 ... See more keywords
Discovery of Clinical Candidate CHF-6366: A Novel Super-soft Dual Pharmacology Muscarinic Antagonist and β2 Agonist (MABA) for the Inhaled Treatment of Respiratory Diseases.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.2c00609
Abstract: The development of molecules embedding two distinct pharmacophores acting as muscarinic antagonists and β2 agonists (MABAs) promises to be an excellent opportunity to reduce formulation issues and boost efficacy through cross-talk and allosteric interactions. Herein,… read more here.
Keywords: clinical candidate; maba; pharmacology; chf 6366 ... See more keywords
CHF6366: characterisation of the bronchoprotective effect of a novel MABA compound in the experimental bronchospasm model in anaesthetised guinea pigs
Sign Up to like & getrecommendations! Published in 2017 at "European Respiratory Journal"
DOI: 10.1183/1393003.congress-2017.oa4405
Abstract: The bronchoprotective effect of CHF6366, a novel dual antimuscarinic and β2 receptor-agonist (MABA) compound, was studied in a model of bronchospasm in anaesthetised guinea pigs that allows discrimination of the two pharmacological activities by using… read more here.
Keywords: maba; anaesthetised guinea; maba compound; effect ... See more keywords